Eli Lilly: amends purchase agreements with US government
(CercleFinance.com) - Eli Lilly today announced an amendment to its purchase agreements with the US government for its neutralizing antibody therapies to treat Covid-19.
The purchase agreement for the delivery of bamlanivimab has been amended: Eli Lilly will supply etesevimab in addition to the bamlanivimab doses already purchased by the US government.
This terminates the contract for the purchase of bamlanivimab alone and cancels the remaining 350,856 doses that were to be delivered by the end of March 2021.
Bamlanivimab was the first neutralising monoclonal antibody to receive emergency approval from the US FDA, Eli Lilly says.
The company subsequently developed a therapy based on the co-administration of bamlanivimab and etesevimab to address the potential challenge of SARS-CoV-2 variants that may be resistant to treatment with either monoclonal antibody used alone.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The purchase agreement for the delivery of bamlanivimab has been amended: Eli Lilly will supply etesevimab in addition to the bamlanivimab doses already purchased by the US government.
This terminates the contract for the purchase of bamlanivimab alone and cancels the remaining 350,856 doses that were to be delivered by the end of March 2021.
Bamlanivimab was the first neutralising monoclonal antibody to receive emergency approval from the US FDA, Eli Lilly says.
The company subsequently developed a therapy based on the co-administration of bamlanivimab and etesevimab to address the potential challenge of SARS-CoV-2 variants that may be resistant to treatment with either monoclonal antibody used alone.
Copyright (c) 2021 CercleFinance.com. All rights reserved.